SEC Form 4 · accession 0001209191-18-063602

Lineage Cell Therapeutics, Inc. · LCTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — General Counsel & Secretary

Period of report

Dec 18, 2018

Accepted (ET)

Dec 20, 2018 · 8:36 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000876343

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares, no par value^F1,F2	Dec 18, 2018	M	27,500	$0.00	A	43,995	D
Common Shares, no par value^F3,F2	Dec 18, 2018	F	9,510	$1.03	D	34,485	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F4	$0.00	Dec 18, 2018	M	27,500	D	—	—	Common Shares	27,500	13,750	D

F1Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018.
F2Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
F3Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 27,500 RSUs, the grant of which was previously reported on a Form 8-K.
F425% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.